Page last updated: 2024-11-03

primaquine and Recrudescence

primaquine has been researched along with Recrudescence in 172 studies

Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.

Research Excerpts

ExcerptRelevanceReference
"Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor."9.30Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019)
"Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain."9.30Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019)
" Artesunate cleared parasitemia significantly faster than chloroquine."9.27Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018)
"25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria."9.07Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994)
"Glucose-6-phosphate dehydrogenase-normal adult volunteers infected with mosquito-bone Chesson strain vivax malaria were treated with chloroquine and primaquine during the initial attack."9.04Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. ( Clyde, DF; McCarthy, VC, 1977)
"Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure')."8.98Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. ( Ashley, EA; Recht, J; White, NJ, 2018)
"We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014."7.83Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016)
"After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria."7.78Reinventing primaquine for endemic malaria. ( Baird, JK, 2012)
" Blood samples were collected for parasite detection (by microscopy and PCR), molecular genotyping and pharmacokinetic analyses."6.94Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan ( Barnes, R; Björkman, A; Kitabi, EN; Mårtensson, A; Mhamilawa, LE; Mmbando, BP; Morris, U; Ngasala, B; Soe, AP, 2020)
" We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P."6.73High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008)
"Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment."6.66Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020)
"Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0."6.61Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019)
"vivax relapse is a major global public health concern."6.53Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016)
"Tafenoquine is a new alternative with a longer half-life."6.52Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015)
"Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia."6.52Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015)
"Plasmodium vivax malaria is considered a major threat to malaria eradication."5.91Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023)
"Malaria is a major cause of death in low-income countries."5.72Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022)
"The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes."5.72Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022)
"Primaquine was effective in preventing P."5.72Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022)
"We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020."5.72Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022)
"vivax malaria was higher in children 1 to <5 years of age (49."5.46Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017)
" We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine."5.40Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014)
"Primaquine phosphate has been used for preventing relapse of Plasmodium vivax and P."5.33Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. ( Baird, JK; Hill, DR; Lewis, LS; Magill, AJ; Parise, ME; Ryan, ET, 2006)
"Primaquine is necessary for the radical cure of Plasmodium vivax malaria, but the optimum duration of treatment and best partner drug are uncertain."5.30Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. ( Bancone, G; Carrara, VI; Chu, CS; Imwong, M; Jeeyapant, A; Lee, SJ; Nosten, F; Paw, MK; Phyo, AP; Poe, NP; Proux, S; Raksapraidee, R; Sriprawat, K; Tarning, J; Thinraow, S; Turner, C; Watson, J; White, NJ; Wiladphaingern, J; Wilairisak, P; Win, HH; Yotyingaphiram, W, 2019)
"Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor."5.30Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. ( Assawariyathipat, T; Assefa, A; Auburn, S; Baird, JK; Chand, K; Chau, NH; Cheah, PY; Day, NP; Degaga, TS; Devine, A; Dhorda, M; Dondorp, A; Dong, LT; Ekawati, LL; Fahmi, F; Hailu, A; Hasanzai, MA; Hien, TT; Khu, H; Ley, B; Lubell, Y; Marfurt, J; Mohammad, H; Moore, KA; Naddim, MN; Pasaribu, AP; Pasaribu, S; Price, RN; Promnarate, C; Rahim, AG; Simpson, JA; Sirithiranont, P; Solomon, H; Sudoyo, H; Sutanto, I; Taylor, WRJ; Thanh, NV; Thriemer, K; Tuyet-Trinh, NT; von Seidlein, L; Waithira, N; White, NJ; Woyessa, A; Yamin, FY; Yuentrakul, P, 2019)
"The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine."5.30[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997)
"Radical cure of Plasmodium vivax malaria requires treatment with a blood schizonticide and a hypnozoitocide (primaquine) to eradicate the dormant liver stages."5.27A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. ( Bava, A; Bhat, K; Brahmarouphu, G; Channabasavaiah, JP; Guddattu, V; Kulavalli, S; Saadi, AV; Saravu, K; Satyamoorthy, K; Srinivas, NK; Tellapragada, C; Umakanth, S; Xavier, W, 2018)
" Artesunate cleared parasitemia significantly faster than chloroquine."5.27Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. ( Aung, AA; Bancone, G; Carrara, VI; Cheah, PY; Chu, CS; Chue, AL; Imwong, M; Lwin, KM; Moore, KA; Nosten, F; Phyo, AP; Proux, S; Raksapraidee, R; San, T; Sriprawat, K; Tarning, J; Watson, J; White, NJ; Wiladphaingern, J; Win, HH; Winterberg, M, 2018)
"Chloroquine has been the standard treatment for Plasmodium vivax malaria for more than 40 years in most regions of the world."5.09Chloroquine sensitivity of Plasmodium vivax in Thailand. ( Bussaratid, V; Chalermrut, K; Chokjindachai, W; Krudsood, S; Looareesuwan, S; Singhasivanon, P; Treeprasertsuk, S; Viriyavejakul, P; Walsh D, S; White, J; Wilairatana, P, 1999)
"In an investigation of relapse patterns, 5541 cases of Plasmodium vivax malaria, from four major industrial complexes, each received at least one, 5-day course of primaquine (at 15 mg/day)."5.09Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India. ( Dua, VK; Sharma, VP, 2001)
"25 mg of base/kg of body weight/day over 14 days) and chloroquine (25 mg of base/kg over 3 days) were compared in 85 adult Thai men with acute Plasmodium vivax malaria."5.07Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. ( Chantra, A; Clemens, R; Pukrittayakamee, S; Vanijanonta, S; White, NJ, 1994)
"Glucose-6-phosphate dehydrogenase-normal adult volunteers infected with mosquito-bone Chesson strain vivax malaria were treated with chloroquine and primaquine during the initial attack."5.04Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. ( Clyde, DF; McCarthy, VC, 1977)
"Chloroquine remains the mainstay of treatment for Plasmodium vivax malaria despite increasing reports of treatment failure."4.98The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. ( Abreha, T; Alemu, SG; Añez, A; Anstey, NM; Awab, GR; Baird, JK; Barber, BE; Borghini-Fuhrer, I; Chu, CS; Commons, RJ; D'Alessandro, U; Dahal, P; Daher, A; de Vries, PJ; Erhart, A; Gomes, MSM; Gonzalez-Ceron, L; Grigg, MJ; Guerin, PJ; Heidari, A; Humphreys, GS; Hwang, J; Kager, PA; Ketema, T; Khan, WA; Lacerda, MVG; Leslie, T; Ley, B; Lidia, K; Monteiro, WM; Nosten, F; Pereira, DB; Phan, GT; Phyo, AP; Price, RN; Rowland, M; Saravu, K; Sibley, CH; Simpson, JA; Siqueira, AM; Stepniewska, K; Sutanto, I; Taylor, WRJ; Thriemer, K; Thwaites, G; Tran, BQ; Tran, HT; Valecha, N; Vieira, JLF; Wangchuk, S; White, NJ; William, T; Woodrow, CJ; Zuluaga-Idarraga, L, 2018)
"Primaquine is the only available antimalarial drug that kills dormant liver stages of Plasmodium vivax and Plasmodium ovale malarias and therefore prevents their relapse ('radical cure')."4.98Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. ( Ashley, EA; Recht, J; White, NJ, 2018)
" Relapse prevention (radical cure) with primaquine is required for optimal management, control and ultimately elimination of Plasmodium vivax malaria."4.93Management of relapsing Plasmodium vivax malaria. ( Chu, CS; White, NJ, 2016)
"We evaluated the efficacy of chloroquine and primaquine on uncomplicated Plasmodium vivax malaria in Cruzeiro do Sul, Brazil, in 2014."3.83Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil. ( Chenet, SM; de Oliveira, AM; de Souza, TM; Farias, S; Marchesini, P; Negreiros, S; Okoth, SA; Povoa, MM; Santelli, AC; Udhayakumar, V; Viana, GM, 2016)
"Control of vivax malaria is challenging due to persistence of hypnozoites causing relapses and safety concerns with primaquine in G6PD deficient individuals."3.81The footprints of relapsing malaria in southwest Delhi, India. ( Anvikar, AR; Nagpal, BN; Savargaonkar, D; Srivastava, B; Valecha, N, 2015)
"Safe treatment of Plasmodium vivax requires diagnosis of both the infection and status of erythrocytic glucose-6-phosphate dehydrogenase (G6PD) activity because hypnozoitocidal therapy against relapse requires primaquine, which causes a mild to severe acute hemolytic anemia in G6PD deficient patients."3.81G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria. ( Baird, JK; Baramuli, V; Coutrier, FN; Elvira, R; Elyazar, I; Harahap, AR; Noviyanti, R; Ridenour, C; Sadhewa, A; Satyagraha, AW, 2015)
"Primaquine (PQ) remains the sole available drug to prevent relapse of Plasmodium vivax malaria more than 60 years after licensure."3.80Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta). ( Gettyacamin, M; Imerbsin, R; Khemawoot, P; Lanteri, C; Nanayakkara, NP; Ohrt, C; Sampath, A; Saunders, D; Siripokasupkul, R; Teja-Isavadharm, P; Tekwani, BL; Vanachayangkul, P; Walker, L, 2014)
"Primaquine is the only drug available for preventing relapse following a primary attack by Plasmodium vivax malaria."3.80The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea. ( Baird, JK; Crenna-Darusallam, C; Ingram, RJ; Noviyanti, R; Soebianto, S, 2014)
"Patients with Plasmodium vivax malaria are treated with primaquine to prevent relapse infections."3.79Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria. ( Alenazi, T; Bright, AT; Houston, S; Paganotti, GM; Shokoples, S; Tarning, J; White, NJ; Winzeler, EA; Yanow, SK, 2013)
"After sixty years of continuous use, primaquine remains the only therapy licensed for arresting transmission and relapse of malaria."3.78Reinventing primaquine for endemic malaria. ( Baird, JK, 2012)
"9 per cent relapse rate after administration of radical treatment of primaquine / 15 mg daily for 5 days as followed under the National Malaria Eradication Programme."3.67Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.). ( Dua, VK; Sharma, VP; Sinha, S, 1989)
"vivax recurrence between days 7 and 90 was investigated by Cox regression analysis."3.01Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Awab, GR; Baird, JK; Brasil, LW; Chu, CS; Commons, RJ; Cui, L; Daher, A; Dini, S; do Socorro M Gomes, M; Gonzalez-Ceron, L; Guerin, PJ; Hwang, J; Karunajeewa, H; Lacerda, MVG; Ladeia-Andrade, S; Leslie, T; Ley, B; Lidia, K; Llanos-Cuentas, A; Longley, RJ; Mehdipour, P; Monteiro, WM; Pereira, DB; Price, RN; Rajasekhar, M; Rijal, KR; Saravu, K; Simpson, JA; Sutanto, I; Taylor, WRJ; Thanh, PV; Thriemer, K; Vieira, JLF; White, NJ; Zaloumis, S; Zuluaga-Idarraga, LM, 2023)
" Blood samples were collected for parasite detection (by microscopy and PCR), molecular genotyping and pharmacokinetic analyses."2.94Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan ( Barnes, R; Björkman, A; Kitabi, EN; Mårtensson, A; Mhamilawa, LE; Mmbando, BP; Morris, U; Ngasala, B; Soe, AP, 2020)
"The median time to recurrence of P."2.94The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. ( Adhikari, B; Cobelens, F; Day, NPJ; Dhorda, M; Dondorp, AM; Henriques, G; Imwong, M; Mayxay, M; Mukaka, M; Newton, PN; Peerawaranun, P; Peto, TJ; Phommasone, K; Pongvongsa, T; Promnarate, C; Sirithiranont, P; van Leth, F; von Seidlein, L; White, NJ, 2020)
"We show that individual vivax malaria recurrences can be characterised probabilistically by combined modelling of time-to-event and genetic data within a framework incorporating identity-by-descent."2.90Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. ( Buckee, CO; Chu, CS; Day, NPJ; Duanguppama, J; Imwong, M; Neafsey, DE; Nosten, F; Puaprasert, K; Taylor, AR; Watson, JA; White, NJ, 2019)
"vivax malaria were treated with AS/SP."2.87Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. ( Abdelbagi, H; Basheir, HM; Boshara, SA; Chen, I; Elobied, ME; Elsafi, HMH; Gosling, R; Gumaa, SA; Hamid, MMA; Hamid, T; Ley, B; Mahgoub, NS; Marfurt, J; Price, RN; Thriemer, K, 2018)
"Some parasite recurrences were detected by PCR and/or serological testing."2.80Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. ( Betanzos, AF; Galindo-Virgen, S; Gonzalez-Ceron, L; Palomeque, OL; Rodriguez, MH; Rosales, AF; Sandoval, MA; Santillan, F, 2015)
" We assessed primaquine (PQ) as hypnozoitocide when administered with dihydroartemisinin-piperaquine (Eurartesim®, DHA-PP) or artesunate-pyronaridine (Pyramax®, AS-PYR) to affirm its good tolerability and efficacy."2.80Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. ( Baird, JK; Basri, H; Chand, K; Djoko, D; Duparc, S; Ekasari, T; Ekawati, LL; Elyazar, I; Nelwan, EJ; Noviyanti, R; Setiabudy, R; Subekti, D; Sudoyo, H; Sutanto, I; Taylor, WR; Tjahjono, B, 2015)
"Primaquine treatment also reduced the risk of quantitative real-time polymerase chain reaction- and light microscopy-positive P."2.77Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. ( Alonso, PL; Bassat, Q; Betuela, I; de Lazzari, E; Del Portillo, HA; Kiniboro, B; Mueller, I; Rosanas-Urgell, A; Samol, L; Siba, P; Stanisic, DI, 2012)
"This suggested that 32 of the 47 recurrences were probable relapses of which 22 (69%) were genetically homologous."2.77Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata. ( Addy, M; Day, NP; Dondorp, AM; Imwong, M; Kim, JR; Maji, AK; Nandy, A; Pukrittayakamee, S; White, NJ, 2012)
"A practical radical treatment for vivax malaria is essential for control and elimination of the disease."2.73A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. ( Erasmus, P; Kolaczinski, J; Leslie, T; Mayan, I; Mohammed, N; Rowland, M; Whitty, CJ, 2008)
" We evaluated the efficacy, safety, and tolerability of alternative primaquine dosing regimens combined with artesunate among 399 Thai patients with acute, symptomatic P."2.73High-dose primaquine regimens against relapse of Plasmodium vivax malaria. ( Baird, JK; Brittenham, GM; Krudsood, S; Looareesuwan, S; Phophak, N; Tangpukdee, N; Wilairatana, P, 2008)
"FDA for the treatment of P."2.72Tafenoquine for ( Gautam, CS; Sharma, J; Singh, H; Singh, J, 2021)
"Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia."2.70Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. ( Ayomi, E; Baird, JK; Basri, H; Fryauff, DJ; Hoffman, SL; Sutanihardja, A; Wiady, I, 2002)
"Halofantrine-primaquine was significantly more effective than chloroquine-primaquine against falciparum malaria (P < 0."2.68Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Harjosuwarno, S; Hoffman, SL; Richie, TL; Subianto, B; Tjitra, E; Wiady, I, 1997)
"Tafenoquine (TQ) is a new alternative to PQ with a longer half-life and can be used as a single-dose treatment."2.66Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, D; Rajapakse, S; Rodrigo, C, 2020)
" We do not know whether there is a difference in adverse events resulting in discontinuation of treatment with the high-standard dosage (RR 4."2.66Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax. ( Bergman, H; Daher, A; Graves, PM; Milligan, R; Villanueva, G, 2020)
"vivax recurrence between days 7 and 42 after starting treatment were investigated by Cox regression analyses according to an a priori analysis plan."2.61The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. ( Abreha, T; Adam, I; Anstey, NM; Assefa, A; Awab, GR; Baird, JK; Barber, BE; Chu, CS; Commons, RJ; Dahal, P; Daher, A; Davis, TME; Dondorp, AM; Grigg, MJ; Guerin, PJ; Hien, TT; Humphreys, GS; Hwang, J; Karunajeewa, H; Laman, M; Lidia, K; Moore, BR; Mueller, I; Nosten, F; Pasaribu, AP; Pereira, DB; Phyo, AP; Poespoprodjo, JR; Price, RN; Sibley, CH; Simpson, JA; Stepniewska, K; Sutanto, I; Thriemer, K; Thwaites, G; White, NJ; William, T; Woodrow, CJ, 2019)
"Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose, or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0."2.61Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria. ( Daher, A; Graves, PM; Milligan, R, 2019)
"Malaria recurrences after an initially successful therapy and malarial fever occurring a long time after infection are well-known problems in malariology."2.53Clinical implications of a gradual dormancy concept in malaria. ( Franken, G; Holtfreter, MC; Labisch, A; Mehlhorn, H; Richter, J; Walter, S, 2016)
"vivax relapse is a major global public health concern."2.53Primaquine treatment and relapse in Plasmodium vivax malaria. ( Rishikesh, K; Saravu, K, 2016)
"Tafenoquine is a new alternative with a longer half-life."2.52Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. ( Fernando, SD; Rajapakse, S; Rodrigo, C, 2015)
"Primaquine was licenced for anti-relapse therapy in 1952 and became available despite threatening patients having an inborn deficiency of glucose-6-phosphate dehydrogenase (G6PD) with acute haemolytic anaemia."2.52Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria. ( Baird, K, 2015)
" For optimal efficacy, treatment regimens must be adjusted with regard to dosage of primaquine and association with halofantrine, mefloquine or other new antimalarial agents."2.41[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax]. ( Granier, H; Klotz, F; Martin, J; Nicolas, X, 2000)
"Plasmodium vivax malaria is considered a major threat to malaria eradication."1.91Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders. ( Aung, PL; Cui, L; Kyaw, MP; Lawpoolsri, S; Linn, NYY; Nguitragool, W; Ring, Z; Sattabongkot, J; Win, KM, 2023)
"Malaria recurrence was defined as more than one episode of vivax malaria in the same or consecutive years."1.72Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients. ( Baek, JH; Cho, SH; Choi, H; Choi, S; Kim, M; Kim, MJ; Kim, YC; Kwak, YG; Kwon, JR; Lee, SE; Oh, HS; Park, S; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022)
"Primaquine was effective in preventing P."1.72Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area. ( Björklund, D; Carlander, C; Färnert, A; Hellgren, U; Hervius Askling, H; Sondén, K; Stenström, C; Wångdahl, A; Wyss, K; Zhang, J, 2022)
"Malaria is a major cause of death in low-income countries."1.72Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine. ( Mohan, M; Nain, M; Sharma, A, 2022)
"The primaquine dose was increased with 30 mg for 14 days at the third and fourth episodes."1.72Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function. ( Baek, JH; Choi, H; Choi, S; Han, JH; Kim, MJ; Kim, YC; Kwak, YG; Oh, HS; Park, SY; Shin, HI; Shin, SY; Song, JE; Yeom, JS, 2022)
"We aimed to investigate malaria recurrences among participants receiving daily and weekly PQ treatments in a real-life setting of two municipalities in the Amazon between 2019 and 2020."1.72Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study. ( Balieiro, PCDS; Brito-Sousa, JD; Cordeiro, JSM; Lacerda, M; Melo, GC; Mendes, M; Monteiro, W; Phanor, J; Sampaio, VS; Silva-Neto, AV; Vitor-Silva, S, 2022)
"Relapses in vivax malaria have posed great challenges for malaria control, and they also account for a great proportion of reported cases."1.62Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria. ( Brito-Sousa, JD; Dinelly, KMO; Lacerda, MVG; Melo, GC; Monteiro, WM; Omena, AG; Peterka, C; Rodovalho, S; Sampaio, VS; Silva, MGO; Siqueira, AM; Vitor-Silva, S, 2021)
"We compare recurrence rates observed after primary P."1.56Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil. ( Corder, RM; Davenport, MP; de Lima, ACP; Docken, SS; Ferreira, MU; Khoury, DS, 2020)
" vivax relapses after a correct treatment and, especially, it should be considered in any study of dosage and duration of primaquine treatment."1.56Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function. ( Bernal Fernández, MJ; Domingo García, D; Gutierrez Liarte, Á; Lanza Suárez, M; Lombardia González, C; Martin Ramírez, A; Rubio, JM; Soler Maniega, T, 2020)
"There was no difference in time to recurrence or recurrence frequency between patients treated with 14-day or 7-9 day primaquine regimens (HR = 1."1.51Evaluation of Plasmodium vivax malaria recurrence in Brazil. ( Daher, A; Fontes, CJ; Lalloo, DG; Marchesini, P; Silva, JCAL; Stevens, A; Ter Kuile, FO, 2019)
"Time to first vivax recurrence was estimated by Kaplan-Meier survival analysis, and risk factors for first and recurrent infections were identified by Cox regression models."1.51Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam. ( A Cleves, M; Aguirre, AR; D'Alessandro, U; Erhart, A; Hens, N; Le, HX; Nguyen, HV; Nguyen, TT; Nguyen, VV; Nguyen, XX; Pham, TV; Rosanas-Urgell, A; Speybroeck, N; Tran, DT, 2019)
"vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0."1.51Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. ( Adhikari, B; Banjara, MR; Chotivanich, K; Das Thakur, G; Day, NPJ; Ghimire, P; Hanboonkunupakarn, B; Imwong, M; Pukrittayakamee, S; Rijal, KR; White, NJ, 2019)
"Ovale malaria is considered to feature relapses by liver hypnozoites although scientific evidence for this paradigm is scarce."1.48Molecular evidence for relapse of an imported Plasmodium ovale wallikeri infection. ( Auer, H; Fuehrer, HP; Groger, M; Lagler, H; Ramharter, M; Veletzky, L; Walochnik, J, 2018)
"vivax malaria episode until the recurrence did not differ between patients with AS of ≤ 1 versus ≥ 1."1.48CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( Almeida, ACG; Brasil, LW; Kühn, A; Lacerda, MVG; Monteiro, WM; Ramasawmy, R; Rodrigues-Soares, F; Santoro, AB; Suarez-Kurtz, G, 2018)
"The developed model to predict recurrence was found to be of good accuracy and could be a useful tool in targeting patients at a higher risk for recurrence for closer monitoring during follow-up, after treatment with primaquine."1.46A clinical tool to predict Plasmodium vivax recurrence in Malaysia. ( Islahudin, F; Kumolosasi, E; Makmor-Bakry, M; Mat Ariffin, N, 2017)
"vivax malaria was higher in children 1 to <5 years of age (49."1.46Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. ( Anstey, NM; Douglas, NM; Kenangalem, E; Malloy, MJ; Patriani, D; Poespoprodjo, JR; Price, RN; Simpson, JA; Soenarto, Y; Sugiarto, P, 2017)
"Plasmodium malariae is the only human malaria parasite species with a 72-hour intraerythrocytic cycle and the ability to persist in the host for life."1.46Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine. ( Anstey, NM; Auburn, S; Berriman, M; Huang, GKL; Marfurt, J; Marr, I; Newbold, CI; Otto, TD; Price, RN; Rutledge, GG; Sanders, M; White, NJ, 2017)
"Two Plasmodium vivax recurrences in a Peruvian sailor with weight above the 60 kg (cap for primaquine dosage) highlight the importance of adequate radical cure weight dosage for patient treatment and control efforts, particularly within the military."1.42Repeated Plasmodium vivax malaria relapses in a Peruvian sailor. ( Cavalcanti, S; Gonzalez, S; Lescano, AG; McFarland, AP; Mercado, A; Sanchez, JF; Ventocilla, JA, 2015)
"Malaria is considered as one of the most threatening diseases affecting peacekeeping forces serving in malaria endemic countries."1.40A retrospective study on imported malaria in Jordan. 1. Malaria among Jordanian UN peacekeeping forces. ( Al-Rashadan, M; Amr, ZS; Bani Hani, R; Kanani, K; Shadfan, B, 2014)
"vivax malaria is a substantial risk."1.40Imported malaria is stable from Africa but declining from Asia. ( David, K; Møller, CH, 2014)
" We report the case of a non-immune traveller, who required high dosage primaquine treatment to obtain radical cure of vivax malaria, emphasizing the importance of country-specific and weight-based dosing of primaquine."1.40Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report. ( Dragsted, UB; Kristensen, KL, 2014)
" The overall median time to relapse, obtained by the Kaplan-Meier method, was 108 days, and the survival analysis demonstrated an association between non-weight-adjusted primaquine dosing and the occurrence of relapse (p < 0."1.38Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil. ( Brasil, P; Campos, DP; Costa, AP; Daniel-Ribeiro, CT; Guaraldo, L; Pedro, RS, 2012)
"Here we describe high rates of P."1.35Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. ( da Silva, NS; da Silva-Nunes, M; Ferreira, MU; Orjuela-Sánchez, P, 2009)
"Relapses were diagnosed in 18% of all malaria episodes."1.33Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center. ( Bottieau, E; Clerinx, J; Colebunders, R; Van Den Ende, J; Van Den Enden, E; Van Esbroeck, M; Van Gompel, A, 2006)
"Primaquine phosphate has been used for preventing relapse of Plasmodium vivax and P."1.33Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. ( Baird, JK; Hill, DR; Lewis, LS; Magill, AJ; Parise, ME; Ryan, ET, 2006)
" Three of these soldiers had received a higher dosage of primaquine (30 mg base daily for 14 days) after their second attack."1.30Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia. ( DeFraites, RF; Kain, KC; Magill, AJ; Smoak, BL; Wellde, BT, 1997)
"The relapses were due to a combination of decreased primaquine sensitivity and incorrect prescription of primaquine."1.30[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment]. ( Dolmans, WM; Mulder, L; Telgt, DS, 1997)
"Primaquine may also cause serious toxic side effects, including methaemoglobin formation and haemolytic anaemia, especially in individuals with erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) deficiency."1.29[Recurrence problems with preventive primaquine treatment in patients with malaria]. ( Bygbjerg, IC; Rønn, AM, 1993)
"Vivax malaria is the most frequent among imported malaria in Japan, comprising about 60% of the total cases."1.29[A study of relapsed cases of vivax malaria after the standard primaquine therapy]. ( Kimura, M; Ohtomo, H; Takizawa, Y; Tomizawa, I, 1996)
"Primaquine has been found adequate to prevent relapse in more than 90% vivax cases, while efficacy of chloroquine-pyrimethamine and chloroquine alone was almost comparable."1.29Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat. ( Bhatt, RM; Sharma, SK; Sharma, VP; Srivastava, HC, 1996)
"Primaquine (30 mg) was given orally to all patients except three; two of these patients received 15 mg of the drug daily and another 30 mg of drug on alternate days."1.28Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. ( Black, JR; Murphy, RL; Noskin, GA; Phair, JP, 1992)
"Chloroquine was most frequently used among antimalarial agents (in 123 cases, 65% of the total) for suppressing acute attacks."1.28[Clinical evaluation of antimalarial drugs]. ( Shimada, K; Tanabe, K, 1990)
"The actual situation of the treatment of malaria for the past 10 years in Japan was investigated and analyzed."1.27Clinical evaluation of antimalarial regimens in Japan. ( Hioki, A; Ishizaki, T; Nakabayashi, T; Ohtomo, H; Tanabe, K, 1987)

Research

Studies (172)

TimeframeStudies, this research(%)All Research%
pre-199024 (13.95)18.7374
1990's28 (16.28)18.2507
2000's20 (11.63)29.6817
2010's69 (40.12)24.3611
2020's31 (18.02)2.80

Authors

AuthorsStudies
Zhang, L1
Sathunuru, R1
Caridha, D1
Pybus, B1
O'Neil, MT1
Kozar, MP1
Lin, AJ1
Aung, PL2
Soe, MT1
Soe, TN1
Oo, TL1
Aung, PP1
Khin, A1
Thi, A1
Phuanukoonnon, S1
Okanurak, K1
Cui, L4
Kyaw, MP2
Parker, DM2
Nain, M1
Mohan, M1
Sharma, A1
Choi, S2
Choi, H2
Park, SY2
Kwak, YG2
Song, JE2
Shin, SY2
Baek, JH2
Shin, HI2
Oh, HS2
Kim, YC2
Yeom, JS3
Han, JH1
Kim, MJ2
Chamma-Siqueira, NN2
Negreiros, SC1
Ballard, SB1
Farias, S2
Silva, SP1
Chenet, SM2
Santos, EJM1
Pereira de Sena, LW1
Póvoa da Costa, F1
Cardoso-Mello, AGN1
Marchesini, PB1
Peterka, CRL1
Viana, GMR2
Macedo de Oliveira, A2
Llanos-Cuentas, A2
Manrrique, P1
Rosas-Aguirre, A1
Herrera, S1
Hsiang, MS1
Gandrala, D2
Gupta, N2
Lavu, A2
Nallapati, VT2
Guddattu, V3
Saravu, K6
Brito-Sousa, JD2
Phanor, J1
Balieiro, PCDS1
Silva-Neto, AV1
Cordeiro, JSM1
Vitor-Silva, S2
Mendes, M1
Sampaio, VS2
Melo, GC2
Lacerda, M1
Monteiro, W1
Watson, JA4
Nekkab, N1
White, M1
Sharma, J1
Gautam, CS1
Singh, H1
Singh, J1
Suh, J1
Kim, JH1
Kim, JD1
Kim, C1
Choi, JY1
Lee, J1
Taylor, WRJ4
Nguyen Pouplin, J1
Daher, A7
White, NJ20
Markus, MB2
Cho, SH1
Lee, SE1
Kwon, JR1
Park, S1
Kim, M1
Win, KM1
Ring, Z1
Linn, NYY1
Nguitragool, W1
Sattabongkot, J1
Lawpoolsri, S1
Mehdipour, P1
Rajasekhar, M1
Dini, S1
Zaloumis, S1
Abreha, T3
Adam, I2
Awab, GR3
Baird, JK14
Brasil, LW2
Chu, CS7
do Socorro M Gomes, M1
Gonzalez-Ceron, L4
Hwang, J3
Karunajeewa, H2
Lacerda, MVG4
Ladeia-Andrade, S1
Leslie, T3
Ley, B5
Lidia, K3
Longley, RJ1
Monteiro, WM4
Pereira, DB3
Rijal, KR2
Sutanto, I5
Thanh, PV1
Thriemer, K5
Vieira, JLF2
Zuluaga-Idarraga, LM2
Guerin, PJ3
Price, RN9
Simpson, JA6
Commons, RJ3
He, X1
Pan, M1
Zeng, W1
Zou, C1
Pi, L1
Qin, Y1
Zhao, L1
Qin, P1
Lu, Y1
Huang, Y1
Yang, Z1
Kostić, M1
Milosavljević, MN1
Stefanović, S1
Ranković, G1
Janković, SM1
Anstey, NM4
Assefa, A2
Barber, BE2
Dahal, P2
Davis, TME1
Dondorp, AM4
Grigg, MJ2
Humphreys, GS2
Laman, M1
Moore, BR1
Mueller, I3
Nosten, F6
Pasaribu, AP2
Phyo, AP4
Poespoprodjo, JR2
Sibley, CH2
Stepniewska, K2
Thwaites, G2
Hien, TT3
William, T2
Woodrow, CJ2
Taylor, AR2
Puaprasert, K1
Duanguppama, J1
Day, NPJ4
Neafsey, DE1
Buckee, CO1
Imwong, M9
Kagaya, W1
Gitaka, J1
Chan, CW1
Kongere, J1
Md Idris, Z1
Deng, C1
Kaneko, A1
Phommasone, K2
van Leth, F2
Henriques, G1
Pongvongsa, T2
Adhikari, B3
Peto, TJ2
Promnarate, C3
Dhorda, M3
Sirithiranont, P2
Mukaka, M2
Peerawaranun, P2
Cobelens, F2
Newton, PN2
von Seidlein, L4
Mayxay, M2
Landier, J1
Nguyen, TN1
Tripura, R1
Lwin, KM2
Kajeechiwa, L1
Thwin, MM1
Wiladphaingern, J3
Nosten, S1
Proux, S3
Nguon, C1
Davoeung, C1
Rekol, H1
Chotivanich, K2
Hanboonkunupakarn, B2
Jittmala, P1
Cheah, PY4
Pukrittayakamee, S5
Thwaites, GE1
Nosten, FH1
Silvino, ACR1
Kano, FS1
Costa, MA1
Fontes, CJF1
Soares, IS2
de Brito, CFA1
Carvalho, LH2
Sousa, TN2
Devine, A2
Howes, RE2
Price, DJ1
Moore, KA3
Dittrich, S1
Spring, MD1
Lon, C1
Sok, S1
Sea, D1
Wojnarski, M1
Chann, S1
Kuntawunginn, W1
Kheang Heng, T1
Nou, S1
Arsanok, M1
Sriwichai, S1
Vanachayangkul, P2
Lin, JT1
Manning, JE1
Jongsakul, K2
Pichyangkul, S1
Satharath, P1
Smith, PL1
Dysoley, L1
Saunders, DL1
Waters, NC1
Mat Salleh, NH1
Rahman, MFA1
Samsusah, S1
De Silva, JR1
Ng, DC1
Ghozali, AH1
Tan, JH1
Lai, MY1
Amir, A1
Liew, JWK1
Lau, YL1
Mhamilawa, LE1
Ngasala, B1
Morris, U1
Kitabi, EN1
Barnes, R1
Soe, AP1
Mmbando, BP1
Björkman, A2
Mårtensson, A1
Martin Ramírez, A1
Lombardia González, C1
Soler Maniega, T1
Gutierrez Liarte, Á1
Domingo García, D1
Lanza Suárez, M1
Bernal Fernández, MJ1
Rubio, JM1
Corder, RM1
de Lima, ACP1
Khoury, DS1
Docken, SS1
Davenport, MP1
Ferreira, MU2
Milligan, R2
Villanueva, G1
Bergman, H1
Graves, PM2
Rodrigo, C2
Rajapakse, S2
Fernando, D1
Dinelly, KMO1
Silva, MGO1
Siqueira, AM2
Peterka, C1
Rodovalho, S1
Omena, AG1
Wångdahl, A1
Sondén, K1
Wyss, K1
Stenström, C1
Björklund, D1
Zhang, J1
Hervius Askling, H1
Carlander, C1
Hellgren, U1
Färnert, A1
Rutledge, GG1
Marr, I1
Huang, GKL1
Auburn, S2
Marfurt, J3
Sanders, M1
Berriman, M1
Newbold, CI1
Otto, TD1
Maneerattanasak, S1
Gosi, P1
Krudsood, S3
Chimma, P1
Tongshoob, J1
Mahakunkijcharoen, Y1
Sukasem, C1
Snounou, G2
Khusmith, S1
Wampfler, R1
Hofmann, NE1
Karl, S1
Betuela, I2
Kinboro, B1
Lorry, L1
Silkey, M1
Robinson, LJ1
Felger, I1
Douglas, NM1
Patriani, D1
Malloy, MJ1
Kenangalem, E1
Sugiarto, P1
Soenarto, Y1
Mat Ariffin, N1
Islahudin, F1
Kumolosasi, E1
Makmor-Bakry, M1
Battle, KE1
Rodrigues-Soares, F1
Santoro, AB1
Almeida, ACG1
Kühn, A1
Ramasawmy, R1
Suarez-Kurtz, G1
Veletzky, L1
Groger, M1
Lagler, H1
Walochnik, J1
Auer, H1
Fuehrer, HP1
Ramharter, M1
Steinkamp, N1
Hamid, MMA1
Elobied, ME1
Mahgoub, NS1
Boshara, SA1
Elsafi, HMH1
Gumaa, SA1
Hamid, T1
Abdelbagi, H1
Basheir, HM1
Chen, I1
Gosling, R1
Recht, J1
Ashley, EA1
Sümer, Ş1
Aktuğ Demir, N1
Ural, O1
Çimen, G1
Yalçınkaya, E1
Win, HH2
San, T1
Aung, AA1
Raksapraidee, R2
Carrara, VI2
Bancone, G2
Watson, J3
Sriprawat, K2
Winterberg, M1
Chue, AL1
Tarning, J3
Alemu, SG1
Añez, A1
Borghini-Fuhrer, I1
D'Alessandro, U2
de Vries, PJ1
Erhart, A2
Gomes, MSM1
Heidari, A1
Kager, PA1
Ketema, T1
Khan, WA1
Phan, GT1
Rowland, M2
Tran, BQ1
Tran, HT1
Valecha, N2
Wangchuk, S1
Zuluaga-Idarraga, L1
Tellapragada, C1
Kulavalli, S1
Xavier, W1
Umakanth, S1
Brahmarouphu, G1
Srinivas, NK1
Channabasavaiah, JP1
Bava, A1
Saadi, AV1
Satyamoorthy, K1
Bhat, K1
Redditt, V1
Bogoch, I1
Rashid, M1
Silva, JCAL1
Stevens, A1
Marchesini, P2
Fontes, CJ3
Ter Kuile, FO1
Lalloo, DG1
Ghimire, P1
Banjara, MR1
Das Thakur, G1
Turner, C1
Poe, NP1
Yotyingaphiram, W1
Thinraow, S1
Wilairisak, P1
Paw, MK1
Lee, SJ1
Jeeyapant, A1
Chen, N1
Dowd, S1
Gatton, ML1
Auliff, A1
Edstein, MD1
Cheng, Q1
Quinn, JC1
McCarthy, S1
Green, JA1
Koh, GCKW1
Duparc, S2
Pham, TV1
Nguyen, HV1
Aguirre, AR1
Nguyen, VV1
A Cleves, M1
Nguyen, XX1
Nguyen, TT1
Tran, DT1
Le, HX1
Hens, N1
Rosanas-Urgell, A2
Speybroeck, N1
Rosenthal, PJ1
Yuentrakul, P1
Assawariyathipat, T1
Chand, K2
Chau, NH1
Dong, LT1
Degaga, TS1
Ekawati, LL2
Fahmi, F1
Hailu, A1
Hasanzai, MA1
Khu, H1
Lubell, Y1
Mohammad, H1
Naddim, MN1
Pasaribu, S1
Rahim, AG1
Solomon, H1
Sudoyo, H2
Thanh, NV1
Tuyet-Trinh, NT1
Waithira, N1
Woyessa, A1
Yamin, FY1
Dondorp, A1
Day, NP3
Bright, AT1
Alenazi, T1
Shokoples, S1
Paganotti, GM1
Houston, S1
Winzeler, EA1
Yanow, SK1
Kristensen, KL1
Dragsted, UB1
Bennett, JW1
Pybus, BS1
Yadava, A1
Tosh, D1
Sousa, JC1
McCarthy, WF1
Deye, G1
Melendez, V1
Ockenhouse, CF1
Nacher, M2
Stefani, A1
Basurko, C2
Lemonnier, D1
Djossou, F1
Demar, M1
Elenga, N1
Brousse, P1
Ville, M1
Carme, B2
Biamonte, MA1
Kanani, K1
Amr, ZS1
Shadfan, B1
Al-Rashadan, M1
Bani Hani, R1
Durand, S1
Cabezas, C1
Lescano, AG2
Galvez, M1
Gutierrez, S1
Arrospide, N1
Alvarez, C1
Santolalla, ML1
Bacon, DJ1
Graf, PC1
Møller, CH1
David, K1
Dos-Santos, JC1
Angerami, RN1
Castiñeiras, CM1
Lopes, SC1
Albrecht, L1
Garcia, MT1
Levy, CE1
Moretti, ML1
Lacerda, MV1
Costa, FT1
Saunders, D1
Imerbsin, R1
Khemawoot, P1
Siripokasupkul, R1
Tekwani, BL1
Sampath, A1
Nanayakkara, NP1
Ohrt, C1
Lanteri, C1
Gettyacamin, M1
Teja-Isavadharm, P1
Walker, L1
Redig, AJ1
Vaidya, A1
Price, C1
Katz, JT1
Maguire, JH1
Ingram, RJ1
Crenna-Darusallam, C1
Soebianto, S1
Noviyanti, R3
Satyagraha, AW1
Sadhewa, A1
Baramuli, V1
Elvira, R1
Ridenour, C1
Elyazar, I2
Coutrier, FN1
Harahap, AR1
Fernando, SD1
Baird, K1
Cheoymang, A1
Ruenweerayut, R1
Muhamad, P1
Rungsihirunrat, K1
Na-Bangchang, K1
Erhardt, J1
Frank, M1
Rodriguez, MH2
Sandoval, MA1
Santillan, F1
Galindo-Virgen, S1
Betanzos, AF1
Rosales, AF1
Palomeque, OL1
McFarland, AP1
Sanchez, JF1
Mercado, A1
Ventocilla, JA1
Cavalcanti, S1
Gonzalez, S1
Siala, E1
Gastli, M1
Essid, R1
Jemal, S1
Ben Abdallah, R1
Ben Abda, I1
Aoun, K1
Bouratbine, A1
Nelwan, EJ1
Tjahjono, B1
Setiabudy, R1
Ekasari, T1
Djoko, D1
Basri, H3
Taylor, WR2
Subekti, D1
Savargaonkar, D1
Nagpal, BN1
Srivastava, B1
Anvikar, AR1
Tamayo Perez, ME1
Aguirre-Acevedo, DC1
Rishikesh, K1
Richter, J1
Franken, G1
Holtfreter, MC1
Walter, S1
Labisch, A1
Mehlhorn, H1
Silvino, AC1
Costa, GL1
Araújo, FC1
Ascher, DB1
Pires, DE1
Brito, CF1
Negreiros, S1
Viana, GM1
Okoth, SA1
de Souza, TM1
Udhayakumar, V1
Povoa, MM1
Santelli, AC1
de Oliveira, AM1
Menard, D1
Kheng, S1
Mayan, I1
Mohammed, N1
Erasmus, P1
Kolaczinski, J1
Whitty, CJ1
Hanf, M1
Stéphani, A1
Orjuela-Sánchez, P1
da Silva, NS1
da Silva-Nunes, M1
Redmond, P1
O'Shea, B1
Crowe, M1
Chiang, TY1
Lin, WC1
Kuo, MC1
Ji, DD1
Fang, CT1
Kim, JR2
Nandy, A2
Maji, AK1
Addy, M1
Pedro, RS1
Guaraldo, L1
Campos, DP1
Costa, AP1
Daniel-Ribeiro, CT1
Brasil, P1
Kiniboro, B1
Stanisic, DI1
Samol, L1
de Lazzari, E1
Del Portillo, HA2
Siba, P1
Alonso, PL1
Bassat, Q1
Wiady, I2
Sutanihardja, A1
Ayomi, E1
Fryauff, DJ2
Hoffman, SL2
Durante Mangoni, E1
Severini, C1
Menegon, M1
Romi, R1
Ruggiero, G1
Majori, G1
Mehrunnisa, A1
Saifi, MA1
Khan, HM1
HANSEN, JE1
CLEVE, EA1
PRUITT, FW1
ARNOLD, J1
ALVING, AS1
HOCKWALD, RS1
CLAYMAN, CB1
DERN, RJ1
BEUTLER, E1
JEFFERY, GM2
Bottieau, E2
Van Gompel, A2
Peetermans, WE1
Clerinx, J1
Van Den Enden, E2
Van Esbroeck, M1
Colebunders, R1
Van Den Ende, J2
Hill, DR1
Parise, ME1
Lewis, LS1
Ryan, ET1
Magill, AJ2
Reddy, P1
Flaherty, JP1
Tanomsing, N1
Guthmann, JP1
Carlton, J1
Looareesuwan, S4
Nair, S1
Sudimack, D1
Anderson, TJ1
Coldren, RL1
Vayakornvichit, S1
Noedl, H1
Fukudas, MM1
Tangpukdee, N1
Wilairatana, P3
Phophak, N1
Brittenham, GM1
Wang, K1
Liu, YL1
Zhang, PN1
Liu, JX1
Appavoo, NC1
Roy, RG2
Kapali, V1
Vittal, M1
Bhate, MR1
Shinde, PH1
Deshpande, SV1
Krotoski, WA2
Horstmann, P1
Jelinek, T1
Nothdurft, HD2
Von Sonnenburg, F1
Loscher, T2
Van den Abbeele, K1
Lazar, AI1
Cranfield, MR1
Graczyk, TK1
Beall, FB1
Ialeggio, DM1
Shaw, ML1
Skjoldager, ML1
Vanijanonta, S1
Chantra, A1
Clemens, R2
Rønn, AM1
Bygbjerg, IC1
Obana, M1
Ohta, S1
Matsuoka, Y1
Irimajiri, S1
Kano, S1
Suzuki, M1
Toma, E2
Fournier, S2
Dumont, M1
Bolduc, P1
Deschamps, H1
Weinke, T1
Kretschmer, H1
Fleischer, K1
Braendli, B1
Markwalder, K1
Schlunk, T1
Bock, HL1
Signorini, L1
Matteelli, A1
Castelnuovo, F1
Castelli, F1
Oladeji, O1
Carosi, G1
Kimura, M1
Tomizawa, I1
Takizawa, Y1
Ohtomo, H2
Smoak, BL1
DeFraites, RF1
Kain, KC2
Wellde, BT1
Bangs, MJ1
Subianto, B1
Harjosuwarno, S1
Tjitra, E1
Richie, TL1
Srivastava, HC1
Sharma, SK1
Bhatt, RM1
Sharma, VP4
Nayar, JK1
Baker, RH1
Knight, JW1
Sullivan, JS2
Morris, CL2
Richardson, BB2
Galland, GG2
Collins, WE4
Telgt, DS1
Mulder, L1
Dolmans, WM1
Buchachart, K1
Chalermrut, K2
Rattanapong, Y1
Amradee, S1
Siripiphat, S1
Chullawichit, S1
Thimasan, K1
Ittiverakul, M1
Triampon, A1
Walsh, DS1
Yi, KJ1
Chung, MH1
Kim, HS1
Kim, CS1
Pai, SH1
Nguyen-Dinh, P1
Nesby, S1
Na, DJ1
Han, JD1
Cha, DY1
Song, IK1
Choi, HW1
Chung, EA1
Park, CW1
Choi, JS1
da Cunha, MG1
Silva, MN1
Souza, JM1
Rodrigues, MM1
Treeprasertsuk, S1
Singhasivanon, P1
Bussaratid, V1
Chokjindachai, W1
Viriyavejakul, P1
Walsh D, S1
White, J1
Hernandez, JE1
Nettel, JA1
Villarreal, C1
Wirtz, RA1
Kroeger, A1
Nicolas, X1
Granier, H1
Martin, J1
Klotz, F1
Duarte, EC1
Pang, LW1
Ribeiro, LC1
Dua, VK2
Khatri, TD1
Owusu-Agyei, S1
Binka, F1
Koram, K1
Anto, F1
Adjuik, M1
Nkrumah, F1
Smith, T1
Clyde, DF1
McCarthy, VC1
Chakrapani, KP1
Dhinagaran, D1
Sitaraman, NL1
Ghosh, RB1
Saint-Yves, IF1
Rossan, RN1
Young, MD1
Baerg, DC1
Noskin, GA1
Murphy, RL1
Black, JR1
Phair, JP1
Nathwani, D1
Currie, PF1
Smith, CC1
Khaund, R1
Stewart, NP1
de Vos, AJ1
Shiels, I1
Tanabe, K2
Shimada, K1
Sharma, RC1
Gautam, AS1
Orlov, V1
Kay, R1
DuBois, RE1
Poisson, M1
Morisset, R1
Phaneuf, D1
Vega, C1
Sinha, S1
McGlone, R1
Mulik, R1
Rombo, L1
Edwards, G1
Ward, SA1
Eriksson, G1
Lindquist, L1
Lindberg, A1
Runehagen, A1
Hylander, NO1
Hioki, A1
Nakabayashi, T1
Ishizaki, T1
Yang, BL1
Wan, WJ1
Wang, WR1
Hu, HX1
Li, HX1
Li, XL1
Li, CZ1
Huang, GZ1
Kumar, A1
Dutta, GP1
Charoenlarp, P1
Harinasuta, T1
Contacos, PG2
Chin, W1
Jeter, MH1
Briesch, PE1
Barrett-Connor, E1
Howard, WA1
Knüttgen, H1
Bruce-Chwatt, LJ1

Clinical Trials (22)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy of Three Regimens of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil[NCT03610399]257 participants (Actual)Interventional2018-04-09Completed
Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094]Phase 4388 participants (Anticipated)Interventional2023-06-26Recruiting
A Randomised, Single-blinded Controlled Treatment Trial of Subclinical Vivax Infections With Primaquine in Nong Province, Laos[NCT02802813]Phase 1/Phase 241 participants (Actual)Interventional2016-06-14Completed
"Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools"[NCT03241901]Phase 4280 participants (Actual)Interventional2017-07-27Completed
Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province[NCT02143934]Phase 4524 participants (Actual)Interventional2009-08-31Completed
Health Care Provider Use of Plasmodium Vivax Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru[NCT05361486]40 participants (Anticipated)Observational2023-08-28Recruiting
Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand[NCT05052502]49,118 participants (Anticipated)Interventional2020-11-01Recruiting
Targeting High-risk Populations With Enhanced Reactive Case Detection: a Study to Assess the Effectiveness and Feasibility for Reducing Plasmodium Falciparum and P. Vivax Malaria in Southern Lao Peoples Democratic Republic[NCT04416945]31,443 participants (Anticipated)Interventional2020-09-20Recruiting
A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan[NCT02592408]Phase 4320 participants (Actual)Interventional2015-11-30Completed
A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border[NCT01074905]Phase 3655 participants (Actual)Interventional2010-05-31Completed
Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax[NCT01640574]Phase 3680 participants (Actual)Interventional2012-02-29Completed
Improving the Radical Cure of Vivax Malaria: A Multicentre Randomised Comparison of Short and Long Course Primaquine Regimens[NCT01814683]2,388 participants (Actual)Interventional2014-07-31Completed
Safety, Tolerability and Pharmacokinetics of Tafenoquine After Weekly and Escalating Monthly Doses of Tafenoquine in Healthy Vietnamese Volunteers[NCT05203744]Phase 4200 participants (Anticipated)Interventional2022-05-10Not yet recruiting
A Clinical Study to Assess the Safety and Feasibility of Controlled Blood-stage Plasmodium Vivax Human Malaria Infection Through Experimental Inoculation of Cryopreserved Infected Erythrocytes in Healthy Thai Adults[NCT05071079]16 participants (Anticipated)Interventional2022-05-23Recruiting
Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GlaxoSmithKline (GSK) Biologicals' Adjuvant System AS01B in Healthy Malaria-Naï[NCT01157897]Phase 1/Phase 241 participants (Actual)Interventional2010-07-31Completed
Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779]Phase 136 participants (Actual)Interventional2017-05-01Completed
Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico[NCT02394197]Phase 4153 participants (Actual)Interventional2008-02-29Completed
Effectiveness of Momordica Charantia Extract Compared to the Standard Antimalarial Drug Combination Dihydroartemisinin Piperaquine-primaquine in Patients With Uncomplicated Falciparum Malaria, in Sumba Barat Daya District of Indonesia[NCT05829187]Phase 236 participants (Actual)Interventional2022-11-01Completed
Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua[NCT06036030]Phase 250 participants (Actual)Interventional2019-01-11Completed
A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.[NCT00158587]Phase 3150 participants (Actual)Interventional2004-04-30Completed
Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT01083095]Early Phase 118 participants (Actual)Interventional2005-01-31Completed
Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380]Phase 218 participants (Actual)Interventional2006-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled

Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 168 days

Interventionparticipants (Number)
Primaquine Regular Dose Unsupervised29
Primaquine Regular Dose Supervised44
Primaquine Double Dose Unsupervised67

Participants With Adequate Clinical and Parasitologic Response Among Patients Enrolled

Participants with adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 28. Those are participants who at day 28 did not present clinical deterioration or presence of parasitemia. (NCT03610399)
Timeframe: 28 days

Interventionparticipants (Number)
Primaquine Regular Dose Unsupervised61
Primaquine Regular Dose Supervised88
Primaquine Double Dose Unsupervised90

Participants With Adequate Clinical and Parasitologic Response Based on Microsatellite-corrected Analysis Per Protocol Day 168

Participants with microsatellite-corrected adequate clinical and parasitologic response among patients enrolled, meaning patients who did not fail treatment by day 168. Those are participants who at day 168 did not present clinical deterioration or presence of parasitemia with homologous (same genotype) parasites. (NCT03610399)
Timeframe: 168 days

InterventionParticipants (Number)
Primaquine Regular Dose Unsupervised29
Primaquine Regular Dose Supervised44
Primaquine Double Dose Unsupervised67

Time to Parasitemia for Immunogenicity Population

"Subjects were ranked according to time of onset of parasitemia and a non-parametric rankorder statistical test (eg, Log-Rank or Mann-Whitney) was performed to evaluate delays in parasitemia induced by vaccination. Cox Proportional Hazards model was used to calculate days to parasitemia and Kaplan-Meier plots were used to display time to first positive malaria blood smear.~Hazard Ratio (HR). Time starts once subject has received t infectious bites. Time stops when subject has first positive blood smear. If subject does not become parasitemic then time stops the day he/she begins anti-malarial therapy." (NCT01157897)
Timeframe: 280 day (during the study through 6 months aftr challenge)

Interventiondays (Mean)
Cohort 1: 15 μg VMP0010.137
Cohort 2: 30 μg VMP0010.073
Cohort 3: 60 μg VMP0010.042

Geometric Mean of Anti-VMP001 Anti-body Titers in Serum Per Efficacy Population

Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration

,,
InterventionGeometric Mean Titier of European Units (Mean)
Pre-vaccination2wks post first vaccinationDay of second vaccination2wks post second vaccinationDay of third vaccination2wks post third vaccination4wks post challenge6mths post challenge
Cohort 1: 15 μg VMP0011133.72244.3520161.189053.3261203.4854843.3810860.7
Cohort 2: 30 μg VMP0011750.381450.2281143.7231071.0168730.456472.1712519.16
Cohort 3: 60 μg VMP0013.09836.681711.6361711.836405.6641879.9932178.395500.73

Geometric Mean of Anti-VMP001 Antibody Titers in Serum Per Immunogenicity Population

Anti-VMP001 antibody concentrations were measured and summarized by geometric mean titers (GMT) with 95% confidence interval (CI). Peak responses were compared by performing Student's t-test on data normalized by log transformation to ascertain the presence or absence of significant dose response differences. ELISA Units (EU) were converted to log10 values for calculations and statistical comparison of geometric means. Units that were reported as '>50' were converted to '1'. (NCT01157897)
Timeframe: study duration

,,
InterventionGeometric Mean Titer of European Units (Mean)
Pre-vaccination2wks post first vaccinationDay of second vaccination2wks post second vaccinationDay of third vaccination2wks post third vaccination4wks post challenge6months post challenge
Cohort 1: 15 μg VMP0011151.39281.7921862.229921.6159883.7754843.3810860.7
Cohort 2: 30 μg VMP0011.5526.181175.4174608.6228498.4368730.456472.1712519.16
Cohort 3: 60 μg VMP0013.09836.681711.6361711.836405.6641879.9932178.395500.73

Occurrence of Solicited Adverse Events Over a 7 Day Follow-up Period After Each Immunization (the Day of the Immunization and 6 Subsequent Days) During the Vaccination Phase

Adverse events were evaluated for 7 days after each vaccination during the vaccine phase. (NCT01157897)
Timeframe: 7 days after immunization

,,
Interventionparticipants with AEs (Number)
Solicited Local: Injection site erythemaSolicited Local: Injection site indurationSolicited Local: Injection site painSolicited Systemic: DiarrheaSolicited Systemic: NauseaSolicited Systemic: VomitingSolicited Systemic: FatigueSolicited Systemic: PyrexiaSolicited Systemic: ArthralgiaSolicited Systemic: MyalgiaSolicited Systemic: Headache
Cohort 1: 15 μg VMP001201005284448
Cohort 2: 30 μg VMP001311003042246
Cohort 3: 60 μg VMP001621014271375

Occurrence of Unsolicited Adverse Events Over a 28 Day Follow-up Period After Each Immunization (the Day of the Immunization and 27 Subsequent Days) During the Vaccination Phase

Adverse events were evaluated over a 28 day follow-up period after each vaccination during the vaccine phase (NCT01157897)
Timeframe: 28 days following immunization

,,
Interventionparticipants with AEs (Number)
Ear discomfortAbdominal discomfortAbdominal painFeces discoloredFood poisoningNauseaToothacheAxillary painChillsFeeling hotInjection site erythemaInjection site pruritusInjection site swellingInjection site warmthMalaiseHypertransaminasaemiaSeasonal allergyNasopharyngitisUpper respiratory tract infectionContusionExcoriationPostprocedural discomfortPosttraumatic painScratchSkin lacerationHaemoglobin decreasedPlatelet count decreasedGoutBack painMuscle spasmsMusculoskeletal discomfortMyalgiaPain in extremityDizzinessHeadacheSinus headacheNasal CongestionCold sweatDermatitis contactErythemaHypertension
Cohort 1: 15 μg VMP00111001120550000311120000000010111211002001
Cohort 2: 30 μg VMP00100000001560021520000010001101000000004110
Cohort 3: 60 μg VMP00100110000771132711021101121101010210112000

Infection for P. Vivax

Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days

Interventiondays (Mean)
Group 111
Group 211
Group 39

Reviews

16 reviews available for primaquine and Recrudescence

ArticleYear
Tafenoquine for the treatment of
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:7

    Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
Tafenoquine for
    The Indian journal of medical research, 2021, Volume: 154, Issue:6

    Topics: Aminoquinolines; Antimalarials; Female; Humans; Malaria, Vivax; Plasmodium vivax; Pregnancy; Primaqu

2021
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
    Malaria journal, 2023, Oct-10, Volume: 22, Issue:1

    Topics: Antimalarials; Folic Acid Antagonists; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurre

2023
The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis.
    PLoS medicine, 2019, Volume: 16, Issue:10

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; Malaria, Vivax; Plas

2019
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    The Cochrane database of systematic reviews, 2020, 08-19, Volume: 8

    Topics: Adult; Antimalarials; Child; Drug Administration Schedule; Glucosephosphate Dehydrogenase; Humans; M

2020
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2020, 09-06, Volume: 9

    Topics: Adult; Aminoquinolines; Antimalarials; Chloroquine; Drug Administration Schedule; Glucosephosphate D

2020
Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries.
    PLoS neglected tropical diseases, 2018, Volume: 12, Issue:4

    Topics: Antimalarials; Chloroquine; Female; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Ma

2018
The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.
    The Lancet. Infectious diseases, 2018, Volume: 18, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dru

2018
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2019, 07-05, Volume: 7

    Topics: Antimalarials; Drug Administration Schedule; Humans; Malaria, Vivax; Primaquine; Primary Prevention;

2019
Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
    The Cochrane database of systematic reviews, 2015, Apr-29, Issue:4

    Topics: Adult; Aminoquinolines; Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, V

2015
Origins and implications of neglect of G6PD deficiency and primaquine toxicity in Plasmodium vivax malaria.
    Pathogens and global health, 2015, Volume: 109, Issue:3

    Topics: Anemia; Antimalarials; Chemical and Drug Induced Liver Injury; Glucosephosphate Dehydrogenase Defici

2015
Therapeutic efficacy of alternative primaquine regimens to standard treatment in preventing relapses by Plasmodium vivax: A systematic review and meta-analysis.
    Colombia medica (Cali, Colombia), 2015, Dec-30, Volume: 46, Issue:4

    Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Administration Schedule; Humans; Malaria,

2015
Primaquine treatment and relapse in Plasmodium vivax malaria.
    Pathogens and global health, 2016, Volume: 110, Issue:1

    Topics: Antimalarials; Humans; Malaria, Vivax; Middle Aged; Plasmodium vivax; Primaquine; Recurrence; Treatm

2016
Clinical implications of a gradual dormancy concept in malaria.
    Parasitology research, 2016, Volume: 115, Issue:6

    Topics: Aminoquinolines; Antimalarials; Humans; Liver; Malaria; Parasitemia; Plasmodium; Plasmodium falcipar

2016
Management of relapsing Plasmodium vivax malaria.
    Expert review of anti-infective therapy, 2016, Volume: 14, Issue:10

    Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Humans; Liver;

2016
[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax].
    Medecine tropicale : revue du Corps de sante colonial, 2000, Volume: 60, Issue:4

    Topics: Antimalarials; Chloroquine; Clinical Protocols; Drug Resistance; Drug Therapy, Combination; Humans;

2000

Trials

33 trials available for primaquine and Recrudescence

ArticleYear
Higher-Dose Primaquine to Prevent Relapse of
    The New England journal of medicine, 2022, 03-31, Volume: 386, Issue:13

    Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Directly Obser

2022
Resolving the cause of recurrent Plasmodium vivax malaria probabilistically.
    Nature communications, 2019, 12-06, Volume: 10, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Female; Humans; Infant; Malaria, Vivax; M

2019
The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR.
    Malaria journal, 2020, Jan-03, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Asymptomatic Infections; Female; Humans; Laos; Malar

2020
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
    PloS one, 2020, Volume: 15, Issue:2

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Cambodia; Child; Female; Humans; Malaria, Falciparum

2020
Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan
    Malaria journal, 2020, Jun-23, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Child; Child, Preschool

2020
Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.
    PLoS neglected tropical diseases, 2017, Volume: 11, Issue:7

    Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Child; Child, Prescho

2017
The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial.
    BMC medical ethics, 2018, 03-06, Volume: 19, Issue:1

    Topics: Biomedical Research; Double-Blind Method; Ethics, Research; Humans; Malaria, Vivax; Patient Selectio

2018
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
    Malaria journal, 2018, Mar-16, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Female; Humans; Infant; Inf

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 10-30, Volume: 67, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Artesunate; Child; Child, Preschool; Chloroquine; Drug Therapy, Co

2018
A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.
    Malaria journal, 2018, Sep-03, Volume: 17, Issue:1

    Topics: Adult; Aged; Antimalarials; Dose-Response Relationship, Drug; Female; Humans; India; Malaria, Vivax;

2018
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019, 04-08, Volume: 68, Issue:8

    Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Administr

2019
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.
    Lancet (London, England), 2019, 09-14, Volume: 394, Issue:10202

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Double-Blind Method; Drug Administration

2019
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    The New England journal of medicine, 2013, Oct-03, Volume: 369, Issue:14

    Topics: Adolescent; Adult; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Male; Metabolism, Inborn

2013
Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru.
    The American journal of tropical medicine and hygiene, 2014, Volume: 91, Issue:1

    Topics: Adolescent; Adult; Aged; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Sc

2014
Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico.
    Malaria journal, 2015, Oct-30, Volume: 14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Child; Child, Preschool; Chloroquine; Dia

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC medicine, 2015, Dec-11, Volume: 13

    Topics: Adult; Antimalarials; Artemisinins; Drug Therapy, Combination; Female; Humans; Indonesia; Malaria, V

2015
A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan.
    PloS one, 2008, Aug-06, Volume: 3, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Drug Adm

2008
Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
    PloS one, 2012, Volume: 7, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Female; Genotype; Genotyping Techniq

2012
Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.
    The Journal of infectious diseases, 2012, Dec-01, Volume: 206, Issue:11

    Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combination; Female; Humans

2012
Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.
    The American journal of tropical medicine and hygiene, 2002, Volume: 66, Issue:6

    Topics: Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Incidence; Indonesia; Malaria, Falcip

2002
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites.
    The Journal of infectious diseases, 2007, Apr-01, Volume: 195, Issue:7

    Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; DNA Primers; Humans; India; Malaria,

2007
High-dose primaquine regimens against relapse of Plasmodium vivax malaria.
    The American journal of tropical medicine and hygiene, 2008, Volume: 78, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Dose-Response Relationship, Drug; Drug Administration Schedule; Fe

2008
Long-term efficacy of primaquine in the treatment of vivax malaria in nonimmune travelers.
    The American journal of tropical medicine and hygiene, 1995, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Aged; Child; Chloroquine; Drug Therapy, Combination; Female; Germany; Humans; Mal

1995
Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria.
    The Journal of infectious diseases, 1994, Volume: 169, Issue:4

    Topics: Adolescent; Adult; Animals; Chloroquine; Drug Resistance; Drug Therapy, Combination; Follow-Up Studi

1994
Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1993, Volume: 17, Issue:2

    Topics: Adult; AIDS-Related Opportunistic Infections; Clindamycin; Double-Blind Method; Drug Therapy, Combin

1993
[Halofantrine in the treatment of imported malaria in nonimmune travelers].
    Deutsche medizinische Wochenschrift (1946), 1993, Feb-26, Volume: 118, Issue:8

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Drug Therapy, Combination; Drug Tolerance; Female;

1993
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.
    Annals of tropical medicine and parasitology, 1997, Volume: 91, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Humans; Indonesia;

1997
Chloroquine sensitivity of Plasmodium vivax in Thailand.
    Annals of tropical medicine and parasitology, 1999, Volume: 93, Issue:3

    Topics: Adolescent; Adult; Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Female; Humans; Mala

1999
Plasmodium vivax relapses after 5 days of primaquine treatment, in some industrial complexes of India.
    Annals of tropical medicine and parasitology, 2001, Volume: 95, Issue:7

    Topics: Antimalarials; Drug Administration Schedule; Follow-Up Studies; Humans; India; Malaria, Vivax; Prima

2001
Does radical cure of asymptomatic Plasmodium falciparum place adults in endemic areas at increased risk of recurrent symptomatic malaria?
    Tropical medicine & international health : TM & IH, 2002, Volume: 7, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Doxycycline; Drug Administration Schedule; Drug Th

2002
Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine.
    The American journal of tropical medicine and hygiene, 1977, Volume: 26, Issue:3

    Topics: Adult; Clinical Trials as Topic; Drug Evaluation; Follow-Up Studies; Humans; Malaria; Male; Plasmodi

1977
Clindamycin with primaquine for Pneumocystis carinii pneumonia.
    Lancet (London, England), 1989, May-13, Volume: 1, Issue:8646

    Topics: Administration, Oral; Clindamycin; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up St

1989
Combined chloroquine-primaquine therapy against vivax malaria.
    The American journal of tropical medicine and hygiene, 1974, Volume: 23, Issue:2

    Topics: Chloroquine; Clinical Trials as Topic; Drug Resistance, Microbial; Humans; Malaria; Plasmodium vivax

1974

Other Studies

123 other studies available for primaquine and Recrudescence

ArticleYear
Antimalarial activities of new guanidylimidazole and guanidylimidazoline derivatives.
    Journal of medicinal chemistry, 2011, Oct-13, Volume: 54, Issue:19

    Topics: Animals; Antimalarials; Crystallography, X-Ray; Guanidines; Humans; Imidazoles; Imidazolines; In Vit

2011
The acceptability of targeted mass treatment with primaquine for local elimination of vivax malaria in a northern Myanmar township: a mixed-methods study.
    Parasites & vectors, 2021, Oct-24, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Cross-Sectional Studies; Disease Eradicat

2021
Effects of Host Genetic Polymorphisms on the Efficacy of the Radical Cure Malaria Drug Primaquine.
    The American journal of tropical medicine and hygiene, 2022, 01-10, Volume: 106, Issue:3

    Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria; Malaria, Vivax; Plasmodiu

2022
Four Times of Relapse of Plasmodium vivax Malaria Despite Primaquine Treatment in a Patient with Impaired Cytochrome P450 2D6 Function.
    The Korean journal of parasitology, 2022, Volume: 60, Issue:1

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax;

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Recurrence in
    F1000Research, 2022, Volume: 11

    Topics: Adult; Antimalarials; Chronic Disease; Follow-Up Studies; Humans; India; Malaria, Vivax; Plasmodium

2022
Effect of weekly versus daily primaquine on Plasmodium vivax malaria recurrences: A real-life cohort study.
    Revista da Sociedade Brasileira de Medicina Tropical, 2022, Volume: 55

    Topics: Antimalarials; Cohort Studies; Humans; Malaria, Vivax; Primaquine; Recurrence

2022
Tafenoquine for the prevention of Plasmodium vivax malaria relapse.
    The Lancet. Microbe, 2021, Volume: 2, Issue:5

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence

2021
Cost-Benefit Analysis of Tafenoquine for Radical Cure of
    Journal of Korean medical science, 2022, Jul-11, Volume: 37, Issue:27

    Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Primaquine; Recurrenc

2022
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2022, 07-21, Volume: 387, Issue:3

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2022, 07-21, Volume: 387, Issue:3

    Topics: Antimalarials; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
    The New England journal of medicine, 2022, 07-21, Volume: 387, Issue:3

    Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2022
How does primaquine prevent Plasmodium vivax malarial recurrences?
    Trends in parasitology, 2022, Volume: 38, Issue:11

    Topics: Animals; Antimalarials; Malaria, Vivax; Mice; Plasmodium vivax; Primaquine; Recurrence

2022
Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients.
    Malaria journal, 2022, Oct-10, Volume: 21, Issue:1

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Cytochrome P450 Family 2; Humans; Malaria, Vivax; Phenotype;

2022
Interventions for promoting patients' adherence to 14-day primaquine treatment in a highly malaria-endemic township in Myanmar: a qualitative study among key stakeholders.
    Malaria journal, 2023, Oct-09, Volume: 22, Issue:1

    Topics: Antimalarials; Humans; Malaria; Malaria, Vivax; Medication Adherence; Myanmar; Plasmodium vivax; Pri

2023
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
    BMC infectious diseases, 2019, Aug-09, Volume: 19, Issue:1

    Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Cytochrome P-450 CYP2D6; Ghana; Humans; Inacti

2019
Killing of Plasmodium vivax by Primaquine and Tafenoquine.
    Trends in parasitology, 2019, Volume: 35, Issue:11

    Topics: Aminoquinolines; Antimalarials; Humans; Hydrogen Peroxide; Malaria, Vivax; Plasmodium vivax; Primaqu

2019
Cost-utility of tafenoquine vs. primaquine for the radical cure (prevention of relapse) of
    Journal of chemotherapy (Florence, Italy), 2020, Volume: 32, Issue:1

    Topics: Aminoquinolines; Antimalarials; Cost-Benefit Analysis; Humans; Malaria, Vivax; Markov Chains; Monte

2020
Malaria resurgence after significant reduction by mass drug administration on Ngodhe Island, Kenya.
    Scientific reports, 2019, 12-13, Volume: 9, Issue:1

    Topics: Anemia; Animals; Antimalarials; Geography; Hemoglobins; Humans; Islands; Kenya; Malaria; Mass Drug A

2019
Novel Insights into Plasmodium vivax Therapeutic Failure: CYP2D6 Activity and Time of Exposure to Malaria Modulate the Risk of Recurrence.
    Antimicrobial agents and chemotherapy, 2020, 04-21, Volume: 64, Issue:5

    Topics: Adolescent; Adult; Antibodies, Protozoan; Antimalarials; Brazil; Child; Cytochrome P-450 CYP2D6; Fem

2020
Cost-Effectiveness Analysis of Sex-Stratified
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:1

    Topics: Adult; Afghanistan; Aminoquinolines; Anemia, Hemolytic; Antimalarials; Chloroquine; Cost-Benefit Ana

2020
Prevalence of CYP2D6 Genotypes and Predicted Phenotypes in a Cohort of Cambodians at High Risk for Infections with
    The American journal of tropical medicine and hygiene, 2020, Volume: 103, Issue:2

    Topics: Antimalarials; Artemisinins; Asian People; Cambodia; Cytochrome P-450 CYP2D6; Drug Therapy, Combinat

2020
Case report: recurrence of Plasmodium vivax malaria due to defective cytochrome P450 2D6 function in Pos Lenjang, Pahang, Malaysia.
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 09-01, Volume: 114, Issue:9

    Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Cytochrome P-450 CYP2D6

2020
Several Plasmodium vivax relapses after correct primaquine treatment in a patient with impaired cytochrome P450 2D6 function.
    Malaria journal, 2020, Jul-17, Volume: 19, Issue:1

    Topics: Antimalarials; Cytochrome P-450 CYP2D6; Female; Humans; Malaria, Vivax; Phenotype; Plasmodium vivax;

2020
Quantifying and preventing Plasmodium vivax recurrences in primaquine-untreated pregnant women: An observational and modeling study in Brazil.
    PLoS neglected tropical diseases, 2020, Volume: 14, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Brazil; Case-Control Studies; Child; Chloroquine; Female; Humans;

2020
Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria.
    Malaria journal, 2021, Jun-13, Volume: 20, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Drug Combinations; Female; Humans; Malaria, Vivax; Male; Middle A

2021
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 04-09, Volume: 74, Issue:7

    Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Plasmodium ovale; Plasmodium vivax;

2022
Genomic Characterization of Recrudescent Plasmodium malariae after Treatment with Artemether/Lumefantrine.
    Emerging infectious diseases, 2017, Volume: 23, Issue:8

    Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Dr

2017
Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.
    Malaria journal, 2017, 05-30, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Drug Resistance; Follow-Up Studies; Genotype; Huma

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
    PLoS medicine, 2017, Volume: 14, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Co

2017
A clinical tool to predict Plasmodium vivax recurrence in Malaysia.
    BMC infectious diseases, 2017, 12-08, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antimalarials; Area Under Curve; Child; Chi

2017
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
    Malaria journal, 2018, Jan-22, Volume: 17, Issue:1

    Topics: Antimalarials; Asia, Southeastern; Cytochrome P-450 CYP2D6; Glucosephosphate Dehydrogenase Deficienc

2018
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
    Malaria journal, 2018, Feb-01, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Cytochrome P-450 CYP

2018
Molecular evidence for relapse of an imported Plasmodium ovale wallikeri infection.
    Malaria journal, 2018, Feb-09, Volume: 17, Issue:1

    Topics: Adolescent; Antimalarials; Artemether, Lumefantrine Drug Combination; Austria; Communicable Diseases

2018
A Malaria Case Followed By Relapse.
    Turkiye parazitolojii dergisi, 2018, Volume: 42, Issue:2

    Topics: Animals; Anopheles; Antimalarials; Chronic Disease; Diagnosis, Differential; Humans; Malaria, Vivax;

2018
A 38-year-old man with fever and a history of malaria.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2018, 09-10, Volume: 190, Issue:36

    Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Malaria, Vivax; Male; Pri

2018
Tafenoquine - A Radical Improvement?
    The New England journal of medicine, 2019, 01-17, Volume: 380, Issue:3

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Primaquine; Recurrence

2019
Evaluation of Plasmodium vivax malaria recurrence in Brazil.
    Malaria journal, 2019, Jan-22, Volume: 18, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Brazil; Child; Child, Presc

2019
Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
    The Journal of infectious diseases, 2019, 07-02, Volume: 220, Issue:3

    Topics: Adolescent; Adult; Antimalarials; Chloroquine; Chronic Disease; Drug Therapy, Combination; Female; F

2019
Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
    Malaria journal, 2019, Apr-18, Volume: 18, Issue:1

    Topics: Alleles; Antimalarials; Australia; Cytochrome P-450 CYP2D6; Humans; Malaria, Vivax; Military Personn

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
    The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. Reply.
    The New England journal of medicine, 2019, 05-09, Volume: 380, Issue:19

    Topics: Aminoquinolines; Humans; Malaria, Vivax; Plasmodium vivax; Primaquine; Recurrence

2019
Plasmodium vivax morbidity after radical cure: A cohort study in Central Vietnam.
    PLoS medicine, 2019, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedule

2019
A shorter course for anti-relapse therapy against vivax malaria.
    Lancet (London, England), 2019, 09-14, Volume: 394, Issue:10202

    Topics: Antimalarials; Chronic Disease; Humans; Malaria, Vivax; Primaquine; Recurrence

2019
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
    Emerging infectious diseases, 2013, Volume: 19, Issue:5

    Topics: Adult; Antimalarials; Biotransformation; Chloroquine; Drug Tolerance; Genome, Protozoan; High-Throug

2013
Recurrent Plasmodium vivax malaria due to dose-dependent primaquine resistance: a case report.
    Scandinavian journal of infectious diseases, 2014, Volume: 46, Issue:1

    Topics: Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaqu

2014
The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana.
    Malaria journal, 2013, Oct-24, Volume: 12

    Topics: Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Prescriptions; Female; Follow-Up Studie

2013
Realistically, how far are we from a universal malaria drug?
    Future medicinal chemistry, 2014, Volume: 6, Issue:2

    Topics: Antimalarials; Artemisinins; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Malaria; P

2014
A retrospective study on imported malaria in Jordan. 1. Malaria among Jordanian UN peacekeeping forces.
    Bulletin de la Societe de pathologie exotique (1990), 2014, Volume: 107, Issue:2

    Topics: Adult; Antimalarials; Cote d'Ivoire; Doxycycline; Drug Therapy, Combination; Endemic Diseases; Eritr

2014
Imported malaria is stable from Africa but declining from Asia.
    Danish medical journal, 2014, Volume: 61, Issue:5

    Topics: Adolescent; Adult; Africa; Aged; Antimalarials; Asia; Atovaquone; Chemoprevention; Child; Child, Pre

2014
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
    Malaria journal, 2014, Jul-22, Volume: 13

    Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini

2014
Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta).
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:12

    Topics: Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Administration Schedule; Drug Ther

2014
Interactive medical case. A chilly fever.
    The New England journal of medicine, 2014, Oct-16, Volume: 371, Issue:16

    Topics: Adult; Antimalarials; Chloroquine; Diagnosis, Differential; Fever; Humans; Life Cycle Stages; Malari

2014
The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
    Malaria journal, 2014, Dec-12, Volume: 13

    Topics: Antimalarials; Doxycycline; Female; Humans; Malaria, Vivax; Middle Aged; New Zealand; Papua New Guin

2014
G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.
    PLoS neglected tropical diseases, 2015, Volume: 9, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antimalarials; Child; Child, Preschool; Female;

2015
Patients' adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border.
    Acta tropica, 2015, Volume: 152

    Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Male;

2015
[13-year old girl with fever 6 months after returning from sub-Saharan Africa].
    Deutsche medizinische Wochenschrift (1946), 2015, Volume: 140, Issue:21

    Topics: Adolescent; Africa; Chloroquine; Developing Countries; Female; Fever of Unknown Origin; Germany; Hum

2015
Repeated Plasmodium vivax malaria relapses in a Peruvian sailor.
    Malaria journal, 2015, Dec-01, Volume: 14

    Topics: Adult; Antimalarials; Body Weight; Genotype; Genotyping Techniques; Humans; Malaria, Vivax; Male; Mi

2015
Late relapse of imported Plasmodium ovale malaria: a case report.
    La Tunisie medicale, 2015, Volume: 93, Issue:6

    Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Cote d'Ivoire; Drug C

2015
The footprints of relapsing malaria in southwest Delhi, India.
    Journal of vector borne diseases, 2015, Volume: 52, Issue:4

    Topics: Adolescent; Antimalarials; Child; Child, Preschool; Female; Humans; India; Infant; Malaria; Male; Pr

2015
Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
    PloS one, 2016, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Antimalarials; Child; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2D6; Female; G

2016
Efficacy of Chloroquine and Primaquine for the Treatment of Uncomplicated Plasmodium vivax Malaria in Cruzeiro do Sul, Brazil.
    The American journal of tropical medicine and hygiene, 2016, Nov-02, Volume: 95, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Brazil; Child; Child, Preschool; Chloroquine; Drug Therapy,

2016
Modelling primaquine-induced haemolysis in G6PD deficiency.
    eLife, 2017, 02-04, Volume: 6

    Topics: Anemia, Hemolytic; Antimalarials; Bayes Theorem; Cell Death; Erythrocytes; Female; Glucosephosphate

2017
Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana.
    Malaria journal, 2009, Dec-04, Volume: 8

    Topics: Animals; Antimalarials; Chloroquine; Cohort Studies; Female; Follow-Up Studies; French Guiana; Human

2009
Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia.
    The American journal of tropical medicine and hygiene, 2009, Volume: 81, Issue:6

    Topics: Animals; Antimalarials; Brazil; Chloroquine; Drug Resistance; Haplotypes; Humans; Malaria, Vivax; Mi

2009
'Not another UTI ... '.
    Age and ageing, 2012, Volume: 41, Issue:4

    Topics: Aged, 80 and over; Antimalarials; Fever; Humans; Malaria; Male; Plasmodium ovale; Primaquine; Recurr

2012
Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2012, Volume: 18, Issue:7

    Topics: Adult; Antimalarials; DNA, Protozoan; Genotype; Humans; Malaria, Vivax; Male; Middle Aged; Oceania;

2012
Plasmodium vivax malaria relapses at a travel medicine centre in Rio de Janeiro, a non-endemic area in Brazil.
    Malaria journal, 2012, Jul-28, Volume: 11

    Topics: Adolescent; Adult; Animals; Antimalarials; Brazil; Female; Humans; Malaria, Vivax; Male; Middle Aged

2012
Reinventing primaquine for endemic malaria.
    Expert opinion on emerging drugs, 2012, Volume: 17, Issue:4

    Topics: Antimalarials; Dose-Response Relationship, Drug; Endemic Diseases; Glucosephosphate Dehydrogenase De

2012
Case report: An unusual late relapse of Plasmodium vivax malaria.
    The American journal of tropical medicine and hygiene, 2003, Volume: 68, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Diagnosis, Differential; DNA, Protozoan; Drug Administration Sc

2003
Prevalence of malaria in Aligarh.
    The Journal of communicable diseases, 2002, Volume: 34, Issue:1

    Topics: Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; India;

2002
Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine.
    The American journal of the medical sciences, 1954, Volume: 227, Issue:1

    Topics: Antimalarials; Chronic Disease; Cyanosis; Humans; Malaria; Malaria, Vivax; Methemoglobinemia; Primaq

1954
The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria.
    The Journal of laboratory and clinical medicine, 1954, Volume: 44, Issue:3

    Topics: Antimalarials; Chronic Disease; Humans; Malaria; Malaria, Vivax; Primaquine; Recurrence

1954
Failure of primaquine therapy for the treatment of Plasmodium ovale malaria.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, Nov-15, Volume: 41, Issue:10

    Topics: Adolescent; Adult; Antimalarials; Humans; Malaria; Male; Plasmodium ovale; Primaquine; Recurrence; T

2005
Imported non-Plasmodium falciparum malaria: a five-year prospective study in a European referral center.
    The American journal of tropical medicine and hygiene, 2006, Volume: 75, Issue:1

    Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Europe; Female; Geography; Humans; Malaria;

2006
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I.
    The American journal of tropical medicine and hygiene, 2006, Volume: 75, Issue:3

    Topics: Adult; Antimalarials; Centers for Disease Control and Prevention, U.S.; Child; Clinical Trials as To

2006
Plasmodium vivax malaria relapses after primaquine prophylaxis.
    Emerging infectious diseases, 2006, Volume: 12, Issue:11

    Topics: Aged; Antimalarials; Humans; Malaria, Vivax; Male; Primaquine; Recurrence

2006
Apparent relapse of imported Plasmodium ovale malaria in a pregnant woman.
    The American journal of tropical medicine and hygiene, 2007, Volume: 77, Issue:5

    Topics: Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria; Plasmodium ovale; Pregnancy; Pr

2007
[Relapses and indirect fluorescent antibody level in vivax malaria patients after chloroquine and chloroquine-primaquine treatment].
    Ji sheng chong xue yu ji sheng chong bing za zhi = Journal of parasitology & parasitic diseases, 1984, Volume: 2, Issue:4

    Topics: Antibodies; Chloroquine; Fluorescent Antibody Technique; Humans; Malaria; Plasmodium vivax; Primaqui

1984
Results of 3-day radical treatment of Plasmodium vivax in North Arcot and South Arcot Districts of Tamil Nadu.
    Indian journal of malariology, 1984, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; Humans;

1984
A note on an interesting case of treatment of Plasmodium vivax curative therapy relapses in a four year old child from Aurangabad, Maharashtra State, India.
    Indian journal of medical sciences, 1982, Volume: 36, Issue:3

    Topics: Child, Preschool; Female; Humans; India; Malaria; Plasmodium vivax; Primaquine; Recurrence

1982
Frequency of relapse and primaquine resistance in Southeast Asian vivax malaria.
    The New England journal of medicine, 1980, Sep-04, Volume: 303, Issue:10

    Topics: Asia, Southeastern; Drug Resistance, Microbial; Humans; Malaria; Plasmodium vivax; Primaquine; Recur

1980
[Prevention of recurrence of malaria with primaquine].
    Ugeskrift for laeger, 1982, May-24, Volume: 144, Issue:21

    Topics: Adult; Child; Child, Preschool; Chloroquine; Follow-Up Studies; Humans; Malaria; Male; Middle Aged;

1982
Combined chloroquine and primaquine resistant Plasmodium vivax malaria in a patient returning from India.
    Annales de la Societe belge de medecine tropicale, 1995, Volume: 75, Issue:1

    Topics: Adult; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Malaria, Vivax; Prim

1995
Halofantrine in acute malaria.
    The Journal of the Association of Physicians of India, 1994, Volume: 42, Issue:5

    Topics: Acute Disease; Antimalarials; Drug Resistance, Multiple; Humans; Malaria, Falciparum; Malaria, Vivax

1994
Subclinical avian malaria infections in African black-footed penguins (Spheniscus demersus) and induction of parasite recrudescence.
    Journal of wildlife diseases, 1994, Volume: 30, Issue:3

    Topics: Animals; Animals, Zoo; Baltimore; Birds; Chloroquine; Dexamethasone; Ducks; Immunosuppression Therap

1994
[Recurrence problems with preventive primaquine treatment in patients with malaria].
    Ugeskrift for laeger, 1993, Nov-29, Volume: 155, Issue:48

    Topics: Adult; Drug Resistance, Microbial; Gastrointestinal Diseases; Humans; Malaria, Falciparum; Malaria,

1993
[A case of vivax malaria in which remission was achieved by primaquine at 1.5 times the standard dose after two earlier relapses].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1993, Volume: 67, Issue:4

    Topics: Adult; Drug Administration Schedule; Humans; Malaria, Vivax; Male; Primaquine; Recurrence; Remission

1993
Short report: primaquine-tolerant Plasmodium vivax in an Italian traveler from Guatemala.
    The American journal of tropical medicine and hygiene, 1996, Volume: 55, Issue:5

    Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Resistance, Microbial; Drug Therapy, Combination; F

1996
[A study of relapsed cases of vivax malaria after the standard primaquine therapy].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1996, Volume: 70, Issue:10

    Topics: Adult; Antimalarials; Asia, Southeastern; Drug Administration Schedule; Humans; Japan; Malaria, Viva

1996
Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
    The American journal of tropical medicine and hygiene, 1997, Volume: 56, Issue:2

    Topics: Adolescent; Adult; Animals; Antimalarials; Drug Resistance; Humans; Malaria, Vivax; Male; Mefloquine

1997
Studies on Plasmodium vivax relapse pattern in Kheda district, Gujarat.
    Indian journal of malariology, 1996, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Therapy, Combination; F

1996
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
    The Journal of parasitology, 1997, Volume: 83, Issue:4

    Topics: Animals; Anopheles; Antimalarials; Aotidae; Brazil; Chloroquine; Disease Models, Animal; Drug Resist

1997
[Recurrent Plasmodium vivax malaria in spite of primaquine follow-up treatment].
    Nederlands tijdschrift voor geneeskunde, 1997, Sep-13, Volume: 141, Issue:37

    Topics: Adult; Antimalarials; Drug Tolerance; Female; Humans; Malaria, Vivax; Male; Middle Aged; Primaquine;

1997
Primaquine-tolerant vivax malaria in Thailand.
    Annals of tropical medicine and parasitology, 1997, Volume: 91, Issue:8

    Topics: Adult; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Stu

1997
A relapsed case of imported tertian malaria after a standard course of hydroxychloroquine and primaquine therapy.
    The Korean journal of parasitology, 1998, Volume: 36, Issue:2

    Topics: Adult; Animals; Antimalarials; Humans; Hydroxychloroquine; Malaria, Vivax; Male; Primaquine; Recurre

1998
Adaptation of a strain of Plasmodium vivax from Mauritania to New World monkeys and anopheline mosquitoes.
    The Journal of parasitology, 1998, Volume: 84, Issue:3

    Topics: Adaptation, Physiological; Animals; Anopheles; Antimalarials; Aotidae; Chloroquine; Disease Models,

1998
Imported tertian malaria resistant to primaquine.
    The Korean journal of internal medicine, 1999, Volume: 14, Issue:2

    Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria, Vivax; Male; Middle Aged; Pla

1999
Longevity of naturally acquired antibody responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1.
    The American journal of tropical medicine and hygiene, 1999, Volume: 60, Issue:3

    Topics: Adult; Animals; Antibodies, Protozoan; Antimalarials; Brazil; Chloroquine; Enzyme-Linked Immunosorbe

1999
Different prevalences of Plasmodium vivax phenotypes VK210 and VK247 associated with the distribution of Anopheles albimanus and Anopheles pseudopunctipennis in Mexico.
    The American journal of tropical medicine and hygiene, 2000, Volume: 62, Issue:1

    Topics: Altitude; Animals; Anopheles; Antibodies, Monoclonal; Antibodies, Protozoan; Antimalarials; Chloroqu

2000
[Does the brief treatment with antimalarials favorably influence drug resistance and recurrences?].
    Revista panamericana de salud publica = Pan American journal of public health, 2001, Volume: 9, Issue:3

    Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Malaria, Falciparum; Malaria,

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria.
    The American journal of tropical medicine and hygiene, 2001, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com

2001
Relapse pattern of Plasmodium vivax in Mumbai: a study of 283 cases of vivax malaria.
    The Journal of the Association of Physicians of India, 2002, Volume: 50

    Topics: Animals; Antimalarials; Humans; India; Malaria, Vivax; Plasmodium vivax; Polymerase Chain Reaction;

2002
Efficacy of 5-day radical treatment of P. vivax infection in Tamil Nadu.
    The Indian journal of medical research, 1977, Volume: 65, Issue:5

    Topics: Adult; Child; Chloroquine; Follow-Up Studies; Humans; India; Malaria; Plasmodium vivax; Primaquine;

1977
Comparison of treatment schedules for Plasmodium vivax infections in the Solomon Islands.
    Papua and New Guinea medical journal, 1977, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Child; Chloroquine; Drug Administration Schedule; Female; Humans; Malaria; Male;

1977
Chemotherapy of Plasmodium vivax in Saimiri and Aotus models.
    The American journal of tropical medicine and hygiene, 1975, Volume: 24, Issue:2

    Topics: Administration, Oral; Animals; Chloroquine; Disease Models, Animal; Drug Combinations; Drug Evaluati

1975
Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1992, Volume: 14, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Aged; Clindamycin; Drug Therapy, Combination; Female; Human

1992
Recurrent plasmodium ovale infection from Papua New Guinea--chloroquine resistance or inadequate primaquine therapy?
    The Journal of infection, 1991, Volume: 23, Issue:3

    Topics: Adult; Humans; Malaria; Male; New Guinea; Primaquine; Recurrence

1991
Elimination of Theileria buffeli infections from cattle by concurrent treatment with primaquine phosphate and halofuginone lactate.
    Tropical animal health and production, 1990, Volume: 22, Issue:2

    Topics: Animals; Antibodies, Protozoan; Antiprotozoal Agents; Apicomplexa; Cattle; Drug Therapy, Combination

1990
[Clinical evaluation of antimalarial drugs].
    Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1990, Volume: 64, Issue:6

    Topics: Adult; Animals; Antimalarials; Chloroquine; Drug Evaluation; Female; Humans; Malaria; Male; Plasmodi

1990
Relapse pattern of Plasmodium vivax in Kheda district, Gujarat.
    Indian journal of malariology, 1990, Volume: 27, Issue:2

    Topics: Animals; Chloroquine; Drug Therapy, Combination; Humans; India; Malaria; Plasmodium vivax; Primaquin

1990
Clindamycin/primaquine therapy and secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS.
    Southern medical journal, 1990, Volume: 83, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; Clindamycin; Drug Administration Sc

1990
Efficacy of 5 day radical treatment of primaquine in Plasmodium vivax cases at the BHEL industrial complex, Hardwar (U.P.).
    Indian journal of malariology, 1989, Volume: 26, Issue:2

    Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Chloroquine; Female; Humans; Infant; Malaria; M

1989
Hypnozoites in Bradford.
    Archives of emergency medicine, 1988, Volume: 5, Issue:4

    Topics: Animals; Child, Preschool; Chloroquine; England; Fever; Humans; Infant, Newborn; Malaria; Male; Plas

1988
Seven patients with relapses of Plasmodium vivax or P. ovale despite primaquine treatment.
    Tropical medicine and parasitology : official organ of Deutsche Tropenmedizinische Gesellschaft and of Deutsche Gesellschaft fur Technische Zusammenarbeit (GTZ), 1987, Volume: 38, Issue:1

    Topics: Adult; Female; Humans; Infant; Malaria; Male; Patient Compliance; Plasmodium; Plasmodium vivax; Prim

1987
Clinical evaluation of antimalarial regimens in Japan.
    Zentralblatt fur Bakteriologie, Mikrobiologie, und Hygiene. Series A, Medical microbiology, infectious diseases, virology, parasitology, 1987, Volume: 264, Issue:3-4

    Topics: Animals; Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Japan; Malaria; Plasmodium f

1987
[Experimental studies on the biological characteristics of Plasmodium vivax in south Yunnan].
    Ji sheng chong xue yu ji sheng chong bing za zhi = Journal of parasitology & parasitic diseases, 1986, Volume: 4, Issue:2

    Topics: Animals; Anopheles; China; Chloroquine; Humans; Malaria; Plasmodium vivax; Primaquine; Recurrence

1986
Tissue schizontocidal activity of minocycline against a relapsing malaria parasite Plasmodium cynomolgi B.
    The Indian journal of medical research, 1987, Volume: 85

    Topics: Animals; Female; Macaca mulatta; Malaria; Male; Minocycline; Plasmodium; Primaquine; Recurrence; Tet

1987
Relapses of vivax malaria after a conventional course of primaquine and chloroquine: report of 2 cases.
    The Southeast Asian journal of tropical medicine and public health, 1973, Volume: 4, Issue:1

    Topics: Adult; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase;

1973
Chemoprophylaxis of malaria for travelers.
    Annals of internal medicine, 1974, Volume: 81, Issue:2

    Topics: Africa; Antimalarials; Asia; Central America; Chloroquine; Dapsone; Drug Resistance, Microbial; Drug

1974
Studies on the characterization of plasmodium vivax strains from Central America.
    The American journal of tropical medicine and hygiene, 1972, Volume: 21, Issue:5

    Topics: Animals; Central America; Chloroquine; Haplorhini; Humans; Lincomycin; Malaria; Plasmodium vivax; Pr

1972
[Letter: Primary long latency in malaria].
    Deutsche medizinische Wochenschrift (1946), 1973, Oct-05, Volume: 98, Issue:40

    Topics: Chloroquine; Malaria; Primaquine; Recurrence; Time Factors

1973
The role of drugs in a malaria program.
    The American journal of tropical medicine and hygiene, 1972, Volume: 21, Issue:5

    Topics: Amodiaquine; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Humans; Malaria; Primaqui

1972
chemdatabank.com